Insulin Lispro vs. Aspart: Are They Interchangeable?

What Was Studied and Why It Matters

Millions of people with diabetes rely on rapid-acting insulin to manage blood sugar spikes after meals. Two of the most commonly prescribed options are insulin lispro (brand names include Humalog) and insulin aspart (brand names include NovoLog). Doctors and patients sometimes need to switch between these insulins — due to cost, insurance changes, supply availability, or a move to biosimilar versions — but questions about whether one works better or is safer than the other have lingered.

A 2024 systematic review published in Expert Opinion on Biological Therapy set out to answer this question by analyzing the best available clinical trial evidence comparing the two insulins head-to-head.

What the Researchers Did

The research team followed strict scientific guidelines (called PRISMA) to search three major medical databases and identify high-quality randomized controlled trials — the gold standard of medical research. From 753 records, they selected nine relevant studies covering both Type 1 diabetes (T1D) and Type 2 diabetes (T2D) in adult patients. They assessed how each insulin affected blood sugar control, dosing, body weight, and safety.

What They Found

The results were clear and consistent: lispro and aspart performed virtually the same across every major measure tested.

• Blood sugar control (HbA1c): Both insulins produced similar reductions in HbA1c — the key long-term marker of diabetes management.
• Low blood sugar episodes (hypoglycemia): Rates were comparable for both Type 1 and Type 2 diabetes patients — neither insulin caused more dangerous lows.
• Dosing and weight changes: No meaningful differences were found between the two.
• Side effects and safety events: Both insulins had similar rates of adverse events, including serious ones, with no clinically significant differences in hyperglycemia, pump infusion site issues, or occlusions.

What This Means for Real Patients

This research provides reassurance that switching between insulin lispro and insulin aspart — or moving to a biosimilar version of either — should not negatively affect your diabetes control or safety. If your insurance plan changes, your pharmacy runs low on one brand, or your doctor recommends a switch, you don't need to worry that one is meaningfully better than the other.

For people using insulin pumps, this is especially helpful news. The finding that infusion site complications were similar between the two means pump users can feel confident if a switch becomes necessary. Whether you source your insulin supplies and pump accessories through a provider like MDS Diabetes or your local pharmacy, knowing your insulin option is flexible adds peace of mind.

Always consult your healthcare provider before making any changes to your insulin regimen, as individual responses can vary and proper guidance ensures a smooth transition.

Bottom Line

Insulin lispro and insulin aspart are equally effective and equally safe for managing mealtime blood sugar in adults with Type 1 or Type 2 diabetes. Doctors and patients can treat them as interchangeable, making insurance transitions, biosimilar switches, and supply changes less stressful and clinically straightforward.